Evidence map›Paper›PMID 39057177›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

Midazolam Indications and Dosing in Palliative Medicine: Results from a Multinational Survey.

Morten Tranung, Tora Skeidsvoll Solheim, Erik Torbjørn Løhre, Kristoffer Marsaa, Dagny Faksvåg Haugen, Barry Laird, Morten Thronæs, Michael Due Larsen

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Morten TranungDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, 7034 Trondheim, Norway.ORCID 0009-0009-6730-5224
Tora Skeidsvoll SolheimDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, 7034 Trondheim, Norway.ORCID 0000-0002-2565-8437
Erik Torbjørn LøhreDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, 7034 Trondheim, Norway.
Kristoffer MarsaaDepartment of Multidisease, Copenhagen University Hospital-North Zealand, 3400 Hilleroed, Denmark.ORCID 0000-0001-7366-7533
Dagny Faksvåg HaugenRegional Centre of Excellence for Palliative Care, Western Norway, Haukeland University Hospital, 5009 Bergen, Norway.
Barry LairdInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh EH8 9YL, UK.
Morten ThronæsDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, 7034 Trondheim, Norway.
Michael Due LarsenDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, 7034 Trondheim, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite sparse evidence and limited guidance on indications, use, and dosing, midazolam is widely used in palliative care. We aimed to describe and compare the use of midazolam in three different countries to improve clinical practice in palliative care. We performed an online survey among palliative care physicians in Norway, Denmark, and the United Kingdom (UK). The focus was indications, dosing, administration, and concomitant drugs. A web-based questionnaire was distributed to members of the respective national palliative medicine associations. The total response rate was 9.4%. Practices in the UK, Norway, and Denmark were overall similar regarding the indications of midazolam for anxiety, dyspnoea, and pain treatment in combination with opioids. However, physicians in the UK used a higher starting dose for anxiety, dyspnoea, and pain treatment compared to Norway and Denmark, as well as a higher maximum dose. Danish physicians preferred, to a higher degree, on-demand midazolam administration. Despite practice similarities in the UK, Norway, and Denmark, differences exist for midazolam dosing and administration in palliative medicine. We demonstrated a lack of consensus on how midazolam should be used in palliative care, setting the stage for future studies on the topic.

Indexed as

MidazolamPalliative CareDenmarkHumansNorwayPalliative MedicinePractice Patterns, Physicians'Surveys and QuestionnairesUnited KingdomMidazolamanxietydyspnoeamidazolampalliative carepalliative medicinesurvey

Identifiers

PMID39057177
PMCPMC11276578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.